{"transactions":[{"id":741351,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:27:20.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3318,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0001193125-26-267634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267634/ownership.xml","form_type":"4"}},{"id":741350,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:27:20.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267634","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267634/ownership.xml","form_type":"4"}},{"id":742201,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:26:17.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":2323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2323,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":2323},"source":{"system":"sec-edgar","filing":"0001193125-26-267629","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000119312526267629/ownership.xml","form_type":"4"}},{"id":742200,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:26:17.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":19909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":19909,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":19909},"source":{"system":"sec-edgar","filing":"0001193125-26-267629","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000119312526267629/ownership.xml","form_type":"4"}},{"id":742199,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:26:17.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267629","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000119312526267629/ownership.xml","form_type":"4"}},{"id":741423,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:25:40.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":4977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":4977,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":4977},"source":{"system":"sec-edgar","filing":"0001193125-26-267623","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000119312526267623/ownership.xml","form_type":"4"}},{"id":741422,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:25:40.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":6636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":6636,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":6636},"source":{"system":"sec-edgar","filing":"0001193125-26-267623","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000119312526267623/ownership.xml","form_type":"4"}},{"id":741421,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:25:40.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267623","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000119312526267623/ownership.xml","form_type":"4"}},{"id":741347,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39189,"kind":"person","name":"Clark William D","position":1,"cik":"0001355415","reported_name":"Clark William D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:23:47.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":2323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2323,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":2323},"source":{"system":"sec-edgar","filing":"0001193125-26-267611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267611/ownership.xml","form_type":"4"}},{"id":741346,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39189,"kind":"person","name":"Clark William D","position":1,"cik":"0001355415","reported_name":"Clark William D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:23:47.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267611","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267611/ownership.xml","form_type":"4"}},{"id":741349,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:21:06.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":3318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3318,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":3318},"source":{"system":"sec-edgar","filing":"0001193125-26-267605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267605/ownership.xml","form_type":"4"}},{"id":741348,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:21:06.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267605","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267605/ownership.xml","form_type":"4"}},{"id":741345,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:20:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":4977,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":4977,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":4977},"source":{"system":"sec-edgar","filing":"0001193125-26-267600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267600/ownership.xml","form_type":"4"}},{"id":741344,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:20:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":5309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":5309,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":5309},"source":{"system":"sec-edgar","filing":"0001193125-26-267600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267600/ownership.xml","form_type":"4"}},{"id":741343,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:20:49.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":70000,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-26-267600","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526267600/ownership.xml","form_type":"4"}},{"id":742185,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:18:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":9756,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":9756},"source":{"system":"sec-edgar","filing":"0001193125-26-267587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000119312526267587/ownership.xml","form_type":"4"}},{"id":742184,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:18:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":84557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after June 9, 2026."}],"balance_after":84557,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":84557},"source":{"system":"sec-edgar","filing":"0001193125-26-267587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000119312526267587/ownership.xml","form_type":"4"}},{"id":747617,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-06-05T20:19:07.000Z","date":"2026-06-03","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":1.6738,"value":418450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.64 to $1.70, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4."}],"balance_after":1721298,"source":{"system":"sec-edgar","filing":"0001193125-26-259637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526259637/ownership.xml","form_type":"4"}},{"id":823974,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Bonus Units","published_at":"2026-03-31T20:17:57.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":true,"shares":632318,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The bonus units vest ratably in equal annual installments over a four-year period beginning on March 27, 2026, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date."}],"balance_after":632318,"derivative":{"underlying":"Common Stock","underlying_shares":632318},"source":{"system":"sec-edgar","filing":"0001193125-26-134631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526134631/ownership.xml","form_type":"4"}},{"id":823973,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-31T20:17:57.000Z","date":"2026-03-27","kind":"grant","planned":false,"acquired":true,"shares":1880510,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2026."}],"balance_after":1880510,"derivative":{"exercise_price":1.77,"expiration_date":"2036-03-26","underlying":"Common Stock","underlying_shares":1880510},"source":{"system":"sec-edgar","filing":"0001193125-26-134631","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526134631/ownership.xml","form_type":"4"}},{"id":832743,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-20T20:17:41.000Z","date":"2026-03-19","kind":"purchase","planned":false,"acquired":true,"shares":70000,"price":1.4,"value":98000.0,"ownership":{"direct":true},"balance_after":195000,"source":{"system":"sec-edgar","filing":"0001193125-26-117675","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000119312526117675/ownership.xml","form_type":"4"}},{"id":833207,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":57074,"kind":"person","name":"Alfieri Michael","position":1,"cik":"0001744687","reported_name":"Alfieri Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-19T21:29:03.000Z","date":"2026-03-18","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":1.42,"value":7100.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001193125-26-116247","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000119312526116247/ownership.xml","form_type":"4"}},{"id":1065103,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":57074,"kind":"person","name":"Alfieri Michael","position":1,"cik":"0001744687","reported_name":"Alfieri Michael","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-15T20:09:59.000Z","date":"2025-08-13","kind":"purchase","planned":false,"acquired":true,"shares":2500,"price":5.3,"value":13250.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000950170-25-109391","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025109391/ownership.xml","form_type":"4"}},{"id":1067637,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2025-08-13T22:03:44.000Z","date":"2025-08-11","kind":"sale","planned":false,"acquired":false,"shares":22073,"price":5.1517,"value":113713.4741,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":221799,"source":{"system":"sec-edgar","filing":"0000950170-25-108210","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025108210/ownership.xml","form_type":"4"}},{"id":1113013,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:38.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":2413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2413,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":2413},"source":{"system":"sec-edgar","filing":"0000950170-25-085489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085489/ownership.xml","form_type":"4"}},{"id":1113012,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:38.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085489/ownership.xml","form_type":"4"}},{"id":1113011,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:30:48.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":2413,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2413,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":2413},"source":{"system":"sec-edgar","filing":"0000950170-25-085475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085475/ownership.xml","form_type":"4"}},{"id":1113010,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:30:48.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085475/ownership.xml","form_type":"4"}},{"id":1113009,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:29:02.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":3860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3860,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":3860},"source":{"system":"sec-edgar","filing":"0000950170-25-085454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085454/ownership.xml","form_type":"4"}},{"id":1113008,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:29:02.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":3619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3619,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":3619},"source":{"system":"sec-edgar","filing":"0000950170-25-085454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085454/ownership.xml","form_type":"4"}},{"id":1113007,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:29:02.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085454","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025085454/ownership.xml","form_type":"4"}},{"id":1114109,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:27:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":1689,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1689,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":1689},"source":{"system":"sec-edgar","filing":"0000950170-25-085441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000095017025085441/ownership.xml","form_type":"4"}},{"id":1114108,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:27:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":14476,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":14476,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":14476},"source":{"system":"sec-edgar","filing":"0000950170-25-085441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000095017025085441/ownership.xml","form_type":"4"}},{"id":1114107,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:27:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085441","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000095017025085441/ownership.xml","form_type":"4"}},{"id":1113071,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:21:47.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":3619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3619,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":3619},"source":{"system":"sec-edgar","filing":"0000950170-25-085419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017025085419/ownership.xml","form_type":"4"}},{"id":1113070,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:21:47.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":4825,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":4825},"source":{"system":"sec-edgar","filing":"0000950170-25-085419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017025085419/ownership.xml","form_type":"4"}},{"id":1113069,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:21:47.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085419","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017025085419/ownership.xml","form_type":"4"}},{"id":1113155,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":78550,"kind":"person","name":"JOYCE MARTIN JOSEPH","position":1,"cik":"0001300858","reported_name":"JOYCE MARTIN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T16:27:30.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":7238,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":7238,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":7238},"source":{"system":"sec-edgar","filing":"0000950170-25-085445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1300858/000095017025085445/ownership.xml","form_type":"4"}},{"id":1113154,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":78550,"kind":"person","name":"JOYCE MARTIN JOSEPH","position":1,"cik":"0001300858","reported_name":"JOYCE MARTIN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T16:27:30.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":1689,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1689,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":1689},"source":{"system":"sec-edgar","filing":"0000950170-25-085445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1300858/000095017025085445/ownership.xml","form_type":"4"}},{"id":1113153,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":78550,"kind":"person","name":"JOYCE MARTIN JOSEPH","position":1,"cik":"0001300858","reported_name":"JOYCE MARTIN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T16:27:30.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":62728,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":62728,"derivative":{"exercise_price":2.685,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":62728},"source":{"system":"sec-edgar","filing":"0000950170-25-085445","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1300858/000095017025085445/ownership.xml","form_type":"4"}},{"id":1169028,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39189,"kind":"person","name":"Clark William D","position":1,"cik":"0001355415","reported_name":"Clark William D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-18T20:41:01.000Z","date":"2025-04-17","kind":"grant","planned":false,"acquired":true,"shares":76760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after April 17, 2025."}],"balance_after":76760,"derivative":{"exercise_price":2.19,"expiration_date":"2035-04-16","underlying":"Common Stock","underlying_shares":76760},"source":{"system":"sec-edgar","filing":"0000950170-25-055900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025055900/ownership.xml","form_type":"4"}},{"id":1176883,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-07T22:43:07.000Z","date":"2025-04-03","kind":"sale","planned":false,"acquired":false,"shares":3400000,"price":1.42,"value":4828000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.18 to $1.78 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":5875851,"source":{"system":"sec-edgar","filing":"0001062993-25-007163","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299325007163/form4.xml","form_type":"4"}},{"id":1219225,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-06T21:17:27.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":809710,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2025."}],"balance_after":809710,"derivative":{"exercise_price":6.17,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":809710},"source":{"system":"sec-edgar","filing":"0000950170-25-034674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025034674/ownership.xml","form_type":"4"}},{"id":1219224,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-06T21:13:41.000Z","date":"2025-03-04","kind":"grant","planned":false,"acquired":true,"shares":202427,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2025."}],"balance_after":202427,"derivative":{"exercise_price":6.17,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":202427},"source":{"system":"sec-edgar","filing":"0000950170-25-034648","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017025034648/ownership.xml","form_type":"4"}},{"id":1383447,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T00:22:37.000Z","date":"2023-04-12","kind":"purchase","planned":false,"acquired":true,"shares":509,"price":10.13,"value":5156.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person.  The Reporting Person only recently become aware of these transactions."}],"balance_after":922,"source":{"system":"sec-edgar","filing":"0000950170-24-116048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024116048/ownership.xml","form_type":"4"}},{"id":1383446,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T00:22:37.000Z","date":"2021-05-03","kind":"purchase","planned":false,"acquired":true,"shares":413,"price":12.81,"value":5290.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The purchases reported herein were executed under the trading discretion of an investment advisor in a managed account, without any instruction from or knowledge of the Reporting Person.  The Reporting Person only recently become aware of these transactions."}],"balance_after":413,"source":{"system":"sec-edgar","filing":"0000950170-24-116048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024116048/ownership.xml","form_type":"4"}},{"id":1433448,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-08-14T20:24:22.000Z","date":"2024-08-12","kind":"sale","planned":false,"acquired":false,"shares":16041,"price":4.7363,"value":75974.9883,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $4.46 to $5.12. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":236771,"source":{"system":"sec-edgar","filing":"0000950170-24-097071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024097071/ownership.xml","form_type":"4"}},{"id":1433892,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":88308,"kind":"person","name":"Greenberg Bruce","position":1,"cik":"0001928391","reported_name":"Greenberg Bruce","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-14T16:24:15.000Z","date":"2024-08-12","kind":"sale","planned":false,"acquired":false,"shares":10834,"price":4.7363,"value":51313.0742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $4.46 to $5.12. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,062 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan."}],"balance_after":126382,"source":{"system":"sec-edgar","filing":"0000950170-24-097070","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1928391/000095017024097070/ownership.xml","form_type":"4"}},{"id":1488881,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:15:15.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":1215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1215,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":1215},"source":{"system":"sec-edgar","filing":"0000950170-24-069900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000095017024069900/ownership.xml","form_type":"4"}},{"id":1488880,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:15:15.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":10418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as the Chairperson of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":10418,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":10418},"source":{"system":"sec-edgar","filing":"0000950170-24-069900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000095017024069900/ownership.xml","form_type":"4"}},{"id":1488879,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36117,"kind":"person","name":"DOUGLAS RICHARD","position":1,"cik":"0001021015","reported_name":"DOUGLAS RICHARD","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:15:15.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069900","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1021015/000095017024069900/ownership.xml","form_type":"4"}},{"id":1488148,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:36.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":1736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1736,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":1736},"source":{"system":"sec-edgar","filing":"0000950170-24-069888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069888/ownership.xml","form_type":"4"}},{"id":1488147,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:36.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069888/ownership.xml","form_type":"4"}},{"id":1488146,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:28.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":1736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1736,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":1736},"source":{"system":"sec-edgar","filing":"0000950170-24-069887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069887/ownership.xml","form_type":"4"}},{"id":1488145,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:28.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069887/ownership.xml","form_type":"4"}},{"id":1488144,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:09.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":2778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2778,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2778},"source":{"system":"sec-edgar","filing":"0000950170-24-069885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069885/ownership.xml","form_type":"4"}},{"id":1488143,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:09.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":2604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2604,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2604},"source":{"system":"sec-edgar","filing":"0000950170-24-069885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069885/ownership.xml","form_type":"4"}},{"id":1488142,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:12:09.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024069885/ownership.xml","form_type":"4"}},{"id":1488185,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:06:46.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":2604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":2604,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2604},"source":{"system":"sec-edgar","filing":"0000950170-24-069874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017024069874/ownership.xml","form_type":"4"}},{"id":1488184,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:06:46.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":3473,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":3473,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":3473},"source":{"system":"sec-edgar","filing":"0000950170-24-069874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017024069874/ownership.xml","form_type":"4"}},{"id":1488183,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T20:06:46.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017024069874/ownership.xml","form_type":"4"}},{"id":1488238,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":78550,"kind":"person","name":"JOYCE MARTIN JOSEPH","position":1,"cik":"0001300858","reported_name":"JOYCE MARTIN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:13:16.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":5209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":5209,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":5209},"source":{"system":"sec-edgar","filing":"0000950170-24-069890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1300858/000095017024069890/ownership.xml","form_type":"4"}},{"id":1488237,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":78550,"kind":"person","name":"JOYCE MARTIN JOSEPH","position":1,"cik":"0001300858","reported_name":"JOYCE MARTIN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:13:16.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":1215,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1215,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":1215},"source":{"system":"sec-edgar","filing":"0000950170-24-069890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1300858/000095017024069890/ownership.xml","form_type":"4"}},{"id":1488236,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":78550,"kind":"person","name":"JOYCE MARTIN JOSEPH","position":1,"cik":"0001300858","reported_name":"JOYCE MARTIN JOSEPH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-06T16:13:16.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":40282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":40282,"derivative":{"exercise_price":4.09,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":40282},"source":{"system":"sec-edgar","filing":"0000950170-24-069890","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1300858/000095017024069890/ownership.xml","form_type":"4"}},{"id":1539772,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-04-17T20:12:37.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":11537,"price":3.164,"value":36503.068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the \"Original Form 4\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Adjusted to reflect 9,317 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment."}],"balance_after":252812,"source":{"system":"sec-edgar","filing":"0000950170-24-045113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024045113/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-12"}},{"id":1540188,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":88308,"kind":"person","name":"Greenberg Bruce","position":1,"cik":"0001928391","reported_name":"Greenberg Bruce","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-04-17T16:10:37.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":13201,"price":3.4064,"value":44967.8864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards.  This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the \"Original Form 4\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Adjusted to reflect 9,455 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment."}],"balance_after":130154,"source":{"system":"sec-edgar","filing":"0000950170-24-045108","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1928391/000095017024045108/ownership.xml","form_type":"4/A","original_submission_date":"2024-03-12"}},{"id":1545961,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T21:32:55.000Z","date":"2024-04-05","kind":"purchase","planned":false,"acquired":true,"shares":37712,"price":4.74,"value":178754.88,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.685 to $4.75 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":9275851,"source":{"system":"sec-edgar","filing":"0001062993-24-008171","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299324008171/form4.xml","form_type":"4"}},{"id":1545960,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-08T21:32:55.000Z","date":"2024-04-04","kind":"purchase","planned":false,"acquired":true,"shares":140281,"price":4.67,"value":655112.27,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.445 to $4.75 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":9238139,"source":{"system":"sec-edgar","filing":"0001062993-24-008171","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299324008171/form4.xml","form_type":"4"}},{"id":1550570,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T21:22:41.000Z","date":"2024-04-03","kind":"purchase","planned":false,"acquired":true,"shares":309847,"price":4.09,"value":1267274.23,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.675 to $4.21 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":9097858,"source":{"system":"sec-edgar","filing":"0001062993-24-007959","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299324007959/form4.xml","form_type":"4"}},{"id":1550569,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T21:22:41.000Z","date":"2024-04-02","kind":"purchase","planned":false,"acquired":true,"shares":186051,"price":3.44,"value":640015.44,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.245 to $3.55 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":8788011,"source":{"system":"sec-edgar","filing":"0001062993-24-007959","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299324007959/form4.xml","form_type":"4"}},{"id":1550568,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-03T21:22:41.000Z","date":"2024-04-01","kind":"purchase","planned":false,"acquired":true,"shares":8374,"price":3.25,"value":27215.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.25 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":8601960,"source":{"system":"sec-edgar","filing":"0001062993-24-007959","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299324007959/form4.xml","form_type":"4"}},{"id":1580569,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T00:04:43.000Z","date":"2024-03-09","kind":"grant","planned":false,"acquired":true,"shares":405450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024."}],"balance_after":405450,"derivative":{"exercise_price":3.62,"expiration_date":"2034-03-08","underlying":"Common Stock","underlying_shares":405450},"source":{"system":"sec-edgar","filing":"0000950170-24-030311","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030311/ownership.xml","form_type":"4"}},{"id":1580568,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:43.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":11537,"price":3.164,"value":36503.068,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":243495,"source":{"system":"sec-edgar","filing":"0000950170-24-030311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030311/ownership.xml","form_type":"4"}},{"id":1580567,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":76594,"kind":"person","name":"Machatha Stephen","position":1,"cik":"0001836354","reported_name":"Machatha Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2024-03-13T00:04:43.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":18231,"price":3.4064,"value":62102.0784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":255032,"source":{"system":"sec-edgar","filing":"0000950170-24-030311","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030311/ownership.xml","form_type":"4"}},{"id":1580566,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-13T00:01:29.000Z","date":"2024-03-09","kind":"grant","planned":false,"acquired":true,"shares":1081201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024."}],"balance_after":1081201,"derivative":{"exercise_price":3.62,"expiration_date":"2034-03-08","underlying":"Common Stock","underlying_shares":1081201},"source":{"system":"sec-edgar","filing":"0000950170-24-030309","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030309/ownership.xml","form_type":"4"}},{"id":1580565,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-13T00:01:29.000Z","date":"2024-03-12","kind":"sale","planned":false,"acquired":false,"shares":85324,"price":3.05,"value":260238.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.00 to $3.11. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1471298,"source":{"system":"sec-edgar","filing":"0000950170-24-030309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030309/ownership.xml","form_type":"4"}},{"id":1580564,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-13T00:01:29.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":97914,"price":3.2735,"value":320521.479,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.35. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1556622,"source":{"system":"sec-edgar","filing":"0000950170-24-030309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017024030309/ownership.xml","form_type":"4"}},{"id":1581750,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":88308,"kind":"person","name":"Greenberg Bruce","position":1,"cik":"0001928391","reported_name":"Greenberg Bruce","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-12T20:07:22.000Z","date":"2024-03-09","kind":"grant","planned":false,"acquired":true,"shares":252280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024."}],"balance_after":252280,"derivative":{"exercise_price":3.62,"expiration_date":"2034-03-08","underlying":"Common Stock","underlying_shares":252280},"source":{"system":"sec-edgar","filing":"0000950170-24-030314","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1928391/000095017024030314/ownership.xml","form_type":"4"}},{"id":1581749,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":88308,"kind":"person","name":"Greenberg Bruce","position":1,"cik":"0001928391","reported_name":"Greenberg Bruce","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-03-12T20:07:22.000Z","date":"2024-03-11","kind":"sale","planned":false,"acquired":false,"shares":13201,"price":3.4064,"value":44967.8864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":120699,"source":{"system":"sec-edgar","filing":"0000950170-24-030314","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1928391/000095017024030314/ownership.xml","form_type":"4"}},{"id":1758291,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T21:15:49.000Z","date":"2023-10-18","kind":"sale","planned":false,"acquired":false,"shares":306499,"price":1.74,"value":533308.26,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.675 to $1.775 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":8593586,"source":{"system":"sec-edgar","filing":"0001062993-23-019546","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323019546/form4.xml","form_type":"4"}},{"id":1758290,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":19219,"kind":"person","name":"PERCEPTIVE ADVISORS LLC","position":1,"cik":"0001224962","reported_name":"PERCEPTIVE ADVISORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19221,"kind":"person","name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","position":2,"cik":"0001249675","reported_name":"PERCEPTIVE LIFE SCIENCES MASTER FUND LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19220,"kind":"person","name":"EDELMAN JOSEPH","position":3,"cik":"0001164426","reported_name":"EDELMAN JOSEPH","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T21:15:49.000Z","date":"2023-10-16","kind":"sale","planned":false,"acquired":false,"shares":2450000,"price":1.6,"value":3920000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $2.03 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of sold at each separate price within such range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the \"Master Fund\").  Perceptive Advisors LLC (the \"Advisor\") serves as the investment manager of Master Fund.  Joseph Edelman is the managing member of the Advisor.  Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes."}],"balance_after":8900085,"source":{"system":"sec-edgar","filing":"0001062993-23-019546","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1164426/000106299323019546/form4.xml","form_type":"4"}},{"id":1783755,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":48021,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":48021},"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783754,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":32953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":32953},"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783753,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":192084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":192084},"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783752,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":73807,"price":7.22,"value":532886.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the exercise of the stock options."}],"balance_after":1654536,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783751,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":48021,"price":0.552,"value":26507.592,"ownership":{"direct":true},"balance_after":1728343,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783750,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":32953,"price":0.552,"value":18190.056,"ownership":{"direct":true},"balance_after":1680322,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783749,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":40835,"kind":"person","name":"Brady Todd C","position":1,"cik":"0001579179","reported_name":"Brady Todd C","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-09-11T21:42:20.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":192084,"price":0.552,"value":106030.368,"ownership":{"direct":true},"balance_after":1647369,"source":{"system":"sec-edgar","filing":"0000950170-23-047530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023047530/ownership.xml","form_type":"4"}},{"id":1783778,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-11T20:31:41.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":false,"shares":5437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":5437},"source":{"system":"sec-edgar","filing":"0000950170-23-047497","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017023047497/ownership.xml","form_type":"4"}},{"id":1783777,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-11T20:31:41.000Z","date":"2023-09-07","kind":"exercise","planned":false,"acquired":true,"shares":5437,"price":0.552,"value":3001.224,"ownership":{"direct":true},"balance_after":14812,"source":{"system":"sec-edgar","filing":"0000950170-23-047497","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017023047497/ownership.xml","form_type":"4"}},{"id":1797508,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-24T20:13:26.000Z","date":"2023-08-22","kind":"exercise","planned":false,"acquired":false,"shares":9604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.552,"expiration_date":"2023-09-07","underlying":"Common Stock","underlying_shares":9604},"source":{"system":"sec-edgar","filing":"0000950170-23-044379","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023044379/ownership.xml","form_type":"4"}},{"id":1797507,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39190,"kind":"person","name":"Walker Neal","position":1,"cik":"0001604457","reported_name":"Walker Neal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-24T20:13:26.000Z","date":"2023-08-22","kind":"exercise","planned":false,"acquired":true,"shares":9604,"price":0.552,"value":5301.408,"ownership":{"direct":true},"balance_after":15854,"source":{"system":"sec-edgar","filing":"0000950170-23-044379","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023044379/ownership.xml","form_type":"4"}},{"id":1835488,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:43:50.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":1372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1372,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":1372},"source":{"system":"sec-edgar","filing":"0000950170-23-031788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017023031788/ownership.xml","form_type":"4"}},{"id":1835487,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:43:50.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":1829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1829,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":1829},"source":{"system":"sec-edgar","filing":"0000950170-23-031788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017023031788/ownership.xml","form_type":"4"}},{"id":1835486,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39205,"kind":"person","name":"Phillips Gary M.","position":1,"cik":"0001197795","reported_name":"Phillips Gary M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:43:50.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":21222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":21222,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":21222},"source":{"system":"sec-edgar","filing":"0000950170-23-031788","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197795/000095017023031788/ownership.xml","form_type":"4"}},{"id":1835431,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:42:39.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":915,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":915,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":915},"source":{"system":"sec-edgar","filing":"0000950170-23-031786","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031786/ownership.xml","form_type":"4"}},{"id":1835430,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":36684,"kind":"person","name":"Miller-Rich Nancy","position":1,"cik":"0001735084","reported_name":"Miller-Rich Nancy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:42:39.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":21222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":21222,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":21222},"source":{"system":"sec-edgar","filing":"0000950170-23-031786","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031786/ownership.xml","form_type":"4"}},{"id":1835429,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:34:59.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":1464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1464,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":1464},"source":{"system":"sec-edgar","filing":"0000950170-23-031781","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031781/ownership.xml","form_type":"4"}},{"id":1835428,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:34:59.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":1372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":1372,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":1372},"source":{"system":"sec-edgar","filing":"0000950170-23-031781","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031781/ownership.xml","form_type":"4"}},{"id":1835427,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39188,"kind":"person","name":"Bronstein Ben","position":1,"cik":"0001604458","reported_name":"Bronstein Ben","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-05T21:34:59.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":21222,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":21222,"derivative":{"exercise_price":8.39,"expiration_date":"2033-06-29","underlying":"Common Stock","underlying_shares":21222},"source":{"system":"sec-edgar","filing":"0000950170-23-031781","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1341235/000095017023031781/ownership.xml","form_type":"4"}}],"next_cursor":"2023-07-05T21:34:59.000000Z,1835427"}